Key result
Ifetroban received FDA Fast Track designation for Duchenne muscular dystrophy cardiomyopathy after a 12-month phase II trial showed net improvement in LVEF and natriuretic peptide.
Answers are grounded in this paper and cite their sources.
The orphan drug ifetroban has completed a phase II clinical trial for Duchenne muscular dystrophy cardiomyopathy and received FDA Fast Track designation, representing a potential targeted therapy for this rare disease.
Patients with Duchenne muscular dystrophy (DMD) face early death from heart failure and have advocated for effective treatments, as current therapies are borrowed from adult heart failure and do not target the cardiomyocyte-driven DMD pathology. Recently, the orphan drug ifetroban successfully completed phase II trial as a specific treatment for DMD cardiomyopathy (NCT03340675) and has been awarded Fast Track status by the Food and Drug Administration. This designation is a step toward a more flexible, patient-centered review process.
No takes yet. Share an insight, caveat, or question.
Carrier et al. (2026) conducted an editorial in Duchenne muscular dystrophy cardiomyopathy. Ifetroban vs. Placebo was evaluated on Left ventricular ejection fraction (LVEF) and circulating natriuretic peptide. Ifetroban received FDA Fast Track designation for Duchenne muscular dystrophy cardiomyopathy after a 12-month phase II trial showed net improvement in LVEF and natriuretic peptide.
Synapse has enriched 10 related papers. Consider them for comparative context: